Pharmaceutical - GlaxoSmithKline, Boehringer Ingelheim

Filter

Popular Filters

Global asthma market to hit $18 billion by 2021 boosted by biologics

Global asthma market to hit $18 billion by 2021 boosted by biologics

14-08-2014

The market for asthma drugs is predicted to reach $18 billion by 2021, according to new research from…

AdvairAsthmaAstraZenecaBoehringer IngelheimBreoGlaxoSmithKlineGlobalMarkets & MarketingNatasha SpillerPharmaceuticalRespiratory and PulmonaryRespiratory therapySpirivaSymbicort

Generic risk to GSK's Advair prompts buy recommendation from analysts

10-09-2013

Pharmaceutical analysts are urging investors to buy shares of UK pharma major GlaxoSmithKline (LSE: GSK)…

AdvairAstraZenecaBoehringer IngelheimEuropeFinancialGlaxoSmithKlinePharmaceuticalRespiratory and PulmonarySandozSpirivaSymbicort

Novel LABA/LAMA products will capture greater market share than the LABA/ICS or LAMA drug classes by 2022

29-08-2013

The drug market for chronic obstructive pulmonary disease (COPD) therapies will see the emergence of…

AdvairAnoroBoehringer IngelheimGlaxoSmithKlineGlobalMarkets & MarketingPharmaceuticalRelvarRespiratory and PulmonarySpirivaTheravance

Pharma giants included in China's investigation into pricing of foreign imports

05-07-2013

China's National Development and Reform Commission (NDRC) has launched an investigation into UK pharma…

Astellas PharmaBaxterBoehringer IngelheimGlaxoSmithKlineJiangsu Hengrui MedicinePharmaceuticalPricingRegulationSandozSinopharm Group

Pipeline anti-diabetic drugs could challenge market-leaders, says Datamonitor

04-07-2013

Pipeline anti-diabetic drugs, including products from US drug major Eli Lilly (NYSE: LLY) and French…

albiglutideAmylinBoehringer IngelheimBydureonDiabetesdulaglutideEli LillyempagliflozinGlaxoSmithKlineInvokanaJohnson & JohnsonLantusNovo NordiskPharmaceuticalSanofiTresibaVictoza

New LABA/LAMA drugs set to fracture COPD market

10-10-2012

The drug market for chronic obstructive pulmonary disease (COPD) therapies will become more fractured…

AdvairBoehringer IngelheimGlaxoSmithKlineGlobalMarkets & MarketingPfizerPharmaceuticalRespiratory and PulmonarySpiriva

Top drugmakers set up non-profit TransCelerate to speed pharma R&D

20-09-2012

Some of the world's leading pharmaceutical companies have formed a non-profit organization to accelerate…

Abbott LaboratoriesAstraZenecaBiotechnologyBoehringer IngelheimBristol-Myers SquibbEli LillyGlaxoSmithKlineJohnson & JohnsonPfizerPharmaceuticalRegulationResearchRocheSanofiTransCelerate BioPharma

Leading dopamine agonists will continue to dominate Parkinson's market

19-08-2012

The leading dopamine agonists, pramipexole (Boehringer Ingelheim's Mirapex/Mirapexin/Sifrol/BI-Sifrol,…

Boehringer IngelheimGlaxoSmithKlineGlobalMarkets & MarketingMirapexNeuproNeurologicalPharmaceuticalRequipRytaryUCB

UK academia-pharma collaboration attracts £14.4 million funding

13-05-2012

In the UK, the University of Dundee and the Medical Research Council (MRC) have announced new funding…

AstraZenecaBoehringer IngelheimEuropeFinancialGlaxoSmithKlineJohnson & JohnsonMerck SeronoPfizerPharmaceuticalResearch

In India, Lilly and Boehringer link for diabetes drug marketing; GSK eyeing acquisitions

04-10-2011

The Indian subsidiaries of US drug major Eli Lilly (NYSE: LLY) and independent German pharma company…

Asia-PacificBoehringer IngelheimDiabetesEli LillyGlaxoSmithKlineMarkets & MarketingMergers & AcquisitionsPharmaceutical

Back to top